Privia Health Group (PRVA) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Privia Health Group in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PRVA shares.
View PRVA analyst ratings or view top-rated stocks.

10 analysts have issued 12 month price objectives for Privia Health Group's stock. Their PRVA share price forecasts range from $28.00 to $43.00. On average, they expect the company's share price to reach $36.86 in the next year. This suggests a possible upside of 65.1% from the stock's current price.
View analysts price targets for PRVA or view top-rated stocks among Wall Street analysts.

Privia Health Group's stock was trading at $22.71 at the beginning of 2023. Since then, PRVA stock has decreased by 1.7% and is now trading at $22.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our PRVA earnings forecast.

Privia Health Group, Inc. (NASDAQ:PRVA) announced its quarterly earnings data on Thursday, August, 3rd. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $0.01. The company had revenue of $413.35 million for the quarter, compared to analysts' expectations of $392.34 million. Privia Health Group had a net margin of 2.26% and a trailing twelve-month return on equity of 6.36%.

ETFs with the largest weight of Privia Health Group (NASDAQ:PRVA) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), BNY Mellon Innovators ETF (BKIV), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Fidelity Disruptive Medicine ETF (FMED), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and Franklin Genomic Advancements ETF (HELX).

Privia Health Group updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.60 billion-$1.65 billion, compared to the consensus revenue estimate of $1.61 billion.

(PRVA) raised $351 million in an initial public offering (IPO) on Thursday, April 29th 2021. The company issued 19,500,000 shares at $17.00-$19.00 per share. Goldman Sachs, J.P. Morgan, Credit Suisse, Piper Sandler and William Blair served as the underwriters for the IPO and Canaccord Genuity, Truist Securities, R. Seelaus & Co. and Siebert Williams Shank were co-managers.

Privia Health Group trades on the NASDAQ under the ticker symbol "PRVA."

Shares of PRVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRVA stock can currently be purchased for approximately $22.32.

Privia Health Group (NASDAQ:PRVA) has a market capitalization of $2.62 billion and generates $1.36 billion in revenue each year. The company earns $-8,590,000.00 in net income (profit) each year or $0.27 on an earnings per share basis.

The company employs 964 workers across the globe.

The official website for the company is www.priviahealth.com. The company can be reached via phone at 571-366-8850 or via email at ir@priviahealth.com.